Notably, AR-driven CLDN8 can activate pro-growth MAPK/AKT signaling in certain contexts, but in ER(+) breast cancer, this may paradoxically reinforce luminal characteristics that endocrine therapy can target effectively [22]. This evidence concerns the gene AKT1 and breast carcinoma.